News

The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). Combining this novel therapeutic strategy with

The two companies will also partner on the development and commercialization of GA Depot. GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting

Pfizer said that the committee has asked it to stop the trial, dubbed Atlas, at a planned interim analysis after finding it to be futile. The recommendation had

The funding will be used to carry out prostate cancer studies over the next five years. More than 40,000 men will be recruited in the prostate cancer trials

New investors include Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, and Venrock Healthcare Partners. Current investors, including The

Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, for which Verastem is seeking full approval for the treatment of relapsed or refractory chronic

IONIS-AZ6-2.5-LRx has been designed by the US company to inhibit an undisclosed target for the treatment of patients having nonalcoholic steatohepatitis (NASH). AstraZeneca and Ionis had previously entered

The trail demonstrated that upadacitinib achieved the primary endpoints of ACR20a and clinical remission remissionb against placebo placebo, as well as achieved all ranked secondary endpoints against either

EpiDestiny is eligible to receive more than 400 million US dollars in upfront, development and sales milestone payments and will get royalties on net sales. EpiDestiny and Novo